EMA Grants Orphan Drug Designation to ChemiCare’s CIC-39 Molecule
Yesterday, May 12, 2022, ChemiCare‘s reference molecule CIC-39, a startup in our network, received orphan drug designation from the European Medicines Agency (EMA) for the treatment of a group of rare genetic diseases associated with Store-Operated Calcium Entry (SOCE) alterations. These include tubular aggregate myopathy, Stormorken syndrome, and York syndrome.
According to the very promising data collected so far, CIC-39 restores intracellular calcium to physiological levels and counters the two main symptoms of these diseases: muscle damage and platelet dysfunction. These effects make it a promising therapeutic strategy for these patients.
“We are extremely pleased with this designation that allows ChemiCare to have the support of the EMA in the next phases of preclinical and clinical studies development, and on the other hand to access dedicated funding for innovative therapeutic strategies in rare diseases.”
Beatrice Riva, CEO, ChemiCare
“The EMA designation to ChemiCare represents a turning point in the startup’s development program and a significant success of our Business NurseryTM. We are happy to have ChemiCare within our startup ecosystem and look forward to working alongside strategic partners to develop ChemiCare’s assets.”comunica
Pietro Conti, CEO, Bio4Dreams